Optimizing clinical use of azathioprine with newer pharmacogenetic data.
Wolverton
Stephen E
SE
D001379:Azathioprine / Q000009:adverse effects* / Q000627:therapeutic use; D003876:Dermatitis, Atopic / Q000188:drug therapy* / Q000276:immunology; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects* / Q000627:therapeutic use; D008297:Male; D020714:Maximum Tolerated Dose; D010597:Pharmacogenetics; D018570:Risk Assessment; D012680:Sensitivity and Specificity; D012872:Skin Diseases, Vesiculobullous / Q000276:immunology; D014657:Vasculitis / Q000188:drug therapy* / Q000276:immunology
D007166:Immunosuppressive Agents; D001379:Azathioprine